UNICA IRIS Institutional Research Information System

PERSANO, MARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 19.844
NA - Nord America 1.700
AS - Asia 1.415
SA - Sud America 177
AF - Africa 34
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 23.175
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 19.307
US - Stati Uniti d'America 1.630
SG - Singapore 555
CN - Cina 391
VN - Vietnam 165
SE - Svezia 141
BR - Brasile 130
DE - Germania 84
FR - Francia 72
HK - Hong Kong 61
IN - India 61
FI - Finlandia 56
GB - Regno Unito 50
CA - Canada 42
NL - Olanda 34
BD - Bangladesh 26
KR - Corea 22
AT - Austria 19
PL - Polonia 18
JP - Giappone 17
AR - Argentina 16
IQ - Iraq 15
MX - Messico 14
TR - Turchia 12
ES - Italia 11
PH - Filippine 10
PK - Pakistan 10
AE - Emirati Arabi Uniti 9
IE - Irlanda 9
MA - Marocco 9
VE - Venezuela 8
ZA - Sudafrica 8
EC - Ecuador 7
ID - Indonesia 7
RU - Federazione Russa 7
SA - Arabia Saudita 7
BE - Belgio 6
IL - Israele 6
IR - Iran 6
TH - Thailandia 6
UZ - Uzbekistan 6
CO - Colombia 5
AU - Australia 4
CH - Svizzera 4
GR - Grecia 4
KG - Kirghizistan 4
TT - Trinidad e Tobago 4
BG - Bulgaria 3
DZ - Algeria 3
JO - Giordania 3
PE - Perù 3
PY - Paraguay 3
AL - Albania 2
AM - Armenia 2
BH - Bahrain 2
BO - Bolivia 2
CL - Cile 2
CR - Costa Rica 2
DM - Dominica 2
DO - Repubblica Dominicana 2
HR - Croazia 2
KE - Kenya 2
LT - Lituania 2
MY - Malesia 2
NG - Nigeria 2
OM - Oman 2
PT - Portogallo 2
RO - Romania 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BJ - Benin 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EG - Egitto 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LY - Libia 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
RS - Serbia 1
SV - El Salvador 1
TN - Tunisia 1
UA - Ucraina 1
UG - Uganda 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 23.175
Salva come PNG Salva come JPEG
Città #
Cagliari 18.161
Uta 989
Singapore 352
Ashburn 230
San Jose 165
Dallas 127
Boardman 99
Nyköping 77
Beijing 74
Los Angeles 68
Hong Kong 57
Chandler 55
Fairfield 51
Ho Chi Minh City 50
Council Bluffs 45
Hanoi 45
Hefei 44
Helsinki 42
New York 38
The Dalles 37
Chicago 32
Santa Clara 30
Rome 29
Seattle 26
Houston 25
Seoul 22
Lauterbourg 21
Munich 21
Shanghai 21
Amsterdam 19
Pune 19
São Paulo 19
Woodbridge 18
Boston 17
Buffalo 17
Cambridge 17
Guangzhou 16
San Diego 16
Wilmington 15
Nuremberg 14
Frankfurt am Main 13
Montreal 13
Orem 13
Redondo Beach 13
Salt Lake City 13
Warsaw 12
Lappeenranta 11
Shenzhen 11
Stockholm 11
Toronto 11
Milan 10
Chennai 9
Düsseldorf 9
London 9
Rio de Janeiro 9
Tianjin 9
Haiphong 8
Roubaix 8
Vienna 8
Dubai 7
Dublin 7
Zhengzhou 7
Brooklyn 6
Da Nang 6
Paris 6
Tashkent 6
Tokyo 6
Atlanta 5
Baghdad 5
Belo Horizonte 5
Florence 5
Manila 5
Menlo Park 5
Naples 5
Phoenix 5
Turin 5
Wuhan 5
Bexley 4
Bishkek 4
Brussels 4
Changsha 4
Charlotte 4
Dong Ket 4
Johannesburg 4
La Maddalena 4
Maebashi 4
Manchester 4
Mexico City 4
Nanjing 4
Poplar 4
Porto Alegre 4
Portsmouth 4
Queens 4
Quito 4
Romainville 4
San Francisco 4
Vancouver 4
Washington 4
Zurich 4
Amman 3
Totale 21.612
Salva come PNG Salva come JPEG
Nome #
Molecular-biology-driven treatment for metastatic colorectal cancer 2.773
New therapeutic targets in pancreatic cancer 1.646
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.547
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment 1.365
Molecular-driven treatment for biliary tract cancer: the promising turning point 1.224
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors 1.088
Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer 997
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 972
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 964
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? 941
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 876
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression 862
Corrigendum: Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients 777
Uncovering key targets of success for immunotherapy in pancreatic cancer 728
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus 679
BRCA-mutant pancreatic ductal adenocarcinoma 620
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging 606
Immune Checkpoint Inhibitors in the Treatment of HCC 596
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment 595
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 387
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 375
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 321
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 318
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 304
Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index 281
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 219
Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer 218
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 211
Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients 208
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 203
Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience 176
Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy 106
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 101
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers 6
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study 6
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 4
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 3
Totale 23.303
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.755
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.755
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202196 0 0 0 0 0 0 0 0 0 0 0 96
2021/20221.411 84 65 4 47 57 107 68 164 112 154 244 305
2022/20233.457 301 460 353 253 266 336 167 257 238 379 291 156
2023/20243.389 144 130 116 191 285 576 596 252 191 206 335 367
2024/20259.142 2.411 2.892 824 954 437 609 481 53 103 161 84 133
2025/20263.355 265 192 244 276 236 234 783 306 232 280 176 131
Totale 23.303